Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
4DMT climbs as gene therapy patients keep jettisoning jabs
4DMT posted 60-week data on a gene therapy, providing evidence of durability in DME and sending its stock up more than 40% in premarket trading.
Nick Paul Taylor
Aug 1, 2025 5:35am
Unity's stock tumbles after eye treatment fails to match Eylea
Mar 24, 2025 11:11am
Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
Jan 7, 2025 9:38am
Merck has clear vision to eye disease assets with $3B EyeBio buy
May 29, 2024 8:32am
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
May 22, 2024 7:15am
Oxurion fails phase 2 eye disease trial, plans bankruptcy filing
Nov 20, 2023 8:30am
